Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling

Regulatory Toxicology and Pharmacology

Volumn 65, Issue 3, 2013, Pages 316-324

  Tsukada, Ai ^a   Suemizu, Hiroshi ^b   Murayama, Norie ^a   Takano, Ryohji ^a,c   Shimizu, Makiko ^a   Nakamura, Masato ^b   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^c Fujitsu Kyusyu Systems   (Japan)

Author keywords

Allometric scaling; No observed adverse effect level; Physiologically based biokinetic model; Simulation; Transplanted human liver

Indexed keywords

MELENGESTROL ACETATE;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FORWARD DOSIMETRY ANALYSIS; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CLEARANCE; LIVER MICROSOME; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

ANIMALS; CELLS, CULTURED; CHIMERA; GLUCOCORTICOIDS; HEPATOCYTES; HUMANS; LIVER; MALE; MELENGESTROL ACETATE; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; MODELS, BIOLOGICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84874555057     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.01.008     Document Type: Article

References (29)

1. Amidon G.L., Sinko P.J., Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res 1988, 5:651-654.
2. Bauer E.R., Daxenberger A., Petri T., Sauerwein H., Meyer H.H. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS 2000, 108:838-846.
3. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 2004, 79:381-393.
4. Cooper J.M., Elce J.S., Kellie A.E. The metabolism of melengestrol acetate. Biochem. J. 1967, 104:57P-58P.
5. Edwards S.W., Preston R.J. Systems biology and mode of action based risk assessment. Toxicol. Sci. 2008, 106:312-318.
6. Elce J.S., Cooper J.M., Kellen E. Plasma levels of melengestrol acetate. Biochem. J. 1967, 104:58P-59P.
7. Emoto C., Murayama N., Rostami-Hodjegan A., Yamazaki H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. Xenobiotica 2009, 39:227-235.
8. Gargas M.L., Andersen M.E., Teo S.K.O., Batra R., Fennell T.R., Kedderis G.L. A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. Toxicol. Appl. Pharmacol. 1995, 134:185-194.
9. Hasegawa M., Kawai K., Mitsui T., Taniguchi K., Monnai M., Wakui M., Ito M., Suematsu M., Peltz G., Nakamura M., Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 2011, 405:405-410.
10. Jamei M., Marciniak S., Feng K., Barnett A., Tucker G., Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 2009, 5:211-223.
11. Joint FAO/WHO Expert Committee, 2009. Evaluation of certain veterinary drug residues in food. World Health Organ Tech. Rep. Ser. 1-134.
12. Kato M., Shitara Y., Sato H., Yoshisue K., Hirano M., Ikeda T., Sugiyama Y. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 2008, 25:1891-1901.
13. Lauderdale J.W., Goyings L.S., Krzeminski L.F., Zimbelman R.G. Studies of a progestogen (MGA) as related to residues and human consumption. J. Toxicol. Environ. Health 1977, 3:5-33.
14. McLanahan E.D., El-Masri H.A., Sweeney L.M., Kopylev L.Y., Clewell H.J., Wambaugh J.F., Schlosser P.M. Physiologically based pharmacokinetic model use in risk assessment - why being published is not enough. Toxicol. Sci. 2012, 126:5-15.
15. Metzler M., Pfeiffer E. Genotoxic potential of xenobiotic growth promoters and their metabolites. APMIS 2001, 109:89-95.
16. Murayama N., Kaneko N., Horiuchi K., Ohyama K., Shimizu M., Ito K., Yamazaki H. Cytochrome P450-dependent drug oxidation activity of liver microsomes from microminipigs, a possible new animal model for humans in non-clinical studies. Drug Metab. Pharmacokinet. 2009, 24:404-408.
17. Patterson D.J., Kiracofe G.H., Stevenson J.S., Corah L.R. Control of the bovine estrous cycle with melengestrol acetate (MGA): a review. J. Anim. Sci. 1989, 67:1895-1906.
18. Perry G.A., Welshons W.V., Bott R.C., Smith M.F. Basis of melengestrol acetate action as a progestin. Domest. Anim. Endocrinol. 2005, 28:147-161.
19. Pfaffl M.W., Daxenberger A., Hageleit M., Meyer H.H. Effects of synthetic progestagens on the mRNA expression of androgen receptor, progesterone receptor, oestrogen receptor alpha and beta, insulin-like growth factor-1 (IGF-1) and IGF-1 receptor in heifer tissues. J. Vet. Med. A Physiol. Pathol. Clin. Med. 2002, 49:57-64.
20. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91:129-156.
21. Schiffer B., Daxenberger A., Meyer K., Meyer H.H. The fate of trenbolone acetate and melengestrol acetate after application as growth promoters in cattle: environmental studies. Environ. Health Persp. 2001, 109:1145-1151.
22. Stephany R.W. Hormonal growth promoting agents in food producing animals. Handb. Exp. Pharmacol. 2010, 355-367.
23. Sweeney L.M., Gargas M.L., Strother D.E., Kedderis G.L. Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci. 2003, 71:27-40.
24. Takano R., Murayama N., Horiuchi K., Kitajima M., Kumamoto M., Shono F., Yamazaki H. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol. 2010, 58:252-258.
25. Wild C.P. Complementing the genome with an " exposome" : the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1847-1850.
26. Yamazaki H., Horiuchi K., Takano R., Nagano T., Shimizu M., Kitajima M., Murayama N., Shono F. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int. J. Environ. Res. Public Health 2010, 7:3406-3421.
27. Yamazaki H., Shimizu M., Nagashima T., Minoshima M., Murayama N. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab. Dispos. 2006, 34:1803-1905.
28. Yamazaki H., Suemizu H., Igaya S., Shimizu M., Shibata M., Nakamura M., Chowdhury G., Guengerich F.P. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem. Res. Toxicol. 2011, 24:287-289.
29. Yamazaki H., Suemizu H., Shimizu M., Igaya S., Shibata N., Nakamura N., Chowdhury G., Guengerich F.P. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem. Res. Toxicol. 2012, 25:274-276.